ValuEngine lowered shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a buy rating to a hold rating in a research note issued to investors on Saturday morning.

PIRS has been the topic of a number of other reports. BidaskClub cut shares of Pieris Pharmaceuticals from a sell rating to a strong sell rating in a report on Saturday, September 15th. HC Wainwright set a $5.00 price target on shares of Pieris Pharmaceuticals and gave the company a buy rating in a report on Wednesday, November 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Pieris Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $10.00.

NASDAQ PIRS opened at $3.18 on Friday. Pieris Pharmaceuticals has a one year low of $3.04 and a one year high of $9.75. The stock has a market cap of $192.77 million, a price-to-earnings ratio of -7.95 and a beta of 1.94.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%. The business had revenue of $8.35 million for the quarter, compared to analysts’ expectations of $6.16 million. As a group, equities research analysts expect that Pieris Pharmaceuticals will post -0.45 earnings per share for the current fiscal year.

In other news, Director Christopher P. Kiritsy purchased 5,000 shares of the stock in a transaction dated Friday, September 14th. The shares were acquired at an average cost of $5.11 per share, for a total transaction of $25,550.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $51,100. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.07% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in PIRS. Public Employees Retirement System of Ohio acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $110,000. Marshall Wace LLP acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $118,000. Fox Run Management L.L.C. acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $124,000. Bowling Portfolio Management LLC acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $156,000. Finally, California Public Employees Retirement System acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $179,000. Institutional investors and hedge funds own 65.22% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: What is a Reverse Stock Split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.